PCSK9 in peripheral arterial disease: Mechanisms and therapeutic perspectives
Science ProgressThis narrative review comprehensively examines the multifaceted roles of proprotein convertase subtilisin/kexin type 9 (PCSK9) in peripheral arterial disease (PAD).
Yue Gao +7 more
doaj +1 more source
SURPASSâCVOT and the Emerging Biology of Cardiometabolic Benefit
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8753-8756, October 2026.
Salvatore Corrao +2 more
wiley +1 more source
PCSK9 Inhibitors and Risk of Aortic Stenosis in Atherosclerotic Cardiovascular Disease. [PDF]
JACC AdvWu JY +4 more
europepmc +1 more source
Breaking Down the Barriers To PCSK9 Inhibitors
Breaking Down the Barriers to PCSK9 inhibitors Abstract Treating high cholesterol with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an important part of risk reduction for coronary artery disease (CAD) (Baum et al., 2017 ...
Perna, Crystal D
core
The Impact of PCSK9 Inhibitors on Circulatory Inflammation: Mechanisms, Evidence, and Application Prospects. [PDF]
JACC AsiaBing-Yan D +7 more
europepmc +1 more source
PCSK9 inhibitors do not increase cognitive risk. [PDF]
Biol DirectNi D +6 more
europepmc +1 more source
PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications. [PDF]
Transl NeurodegenerWang JDJ +8 more
europepmc +1 more source
Correction: A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]
Front PharmacolLiu HH, Li S, Li JJ.
europepmc +1 more source
The effect of PCSK9 inhibitors on cardiovascular outcomes in diabetic patients: a narrative review. [PDF]
Front PharmacolKhalid Sharafeldin AB +4 more
europepmc +1 more source
A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]
Front PharmacolLiu HH, Li S, Li JJ.
europepmc +1 more source